CS
NVAX icon

Credit Suisse’s Novavax NVAX Stock Holding History

Credit Suisse’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-61,800
Closed -$8.84M – 4107
2021
Q4 		$8.84M Buy
61,800
+56,500
+1,066% +$9.71M ﹤0.01% 1595
2021
Q3 		$1.1M Buy
+5,300
New +$1.17M ﹤0.01% 3271
2021
Q2 		– Sell
-62,600
Closed -$11.3M – 4564
2021
Q1 		$11.3M Sell
62,600
-58,700
-48% -$11.7M 0.01% 1497
2020
Q4 		$13.5M Buy
+121,300
New +$12.9M 0.01% 1396

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Credit Suisse's NVAX Position: Q1 2024 in Review

Credit Suisse reduced its Novavax (NVAX) stake by 10% in Q1 2024, selling an estimated $218K and leaving 405,846 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Credit Suisse first reported a position in NVAX in Q2 2013 and has held it in 42 quarters since. The position peaked at $58.5M in Q3 2021. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Credit Suisse held 405,846 shares of Novavax worth $1.94M as of Q1 2024.
  • Credit Suisse sold 46,931 Novavax shares in Q1 2024, an estimated $218K.
  • Novavax made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1871 holding.
  • Credit Suisse first reported a position in Novavax in Q2 2013 and has held it in 42 quarters since.
  • Credit Suisse's Novavax position peaked at $58.5M in Q3 2021.
  • 201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.